Unicycive Therapeutics Inc Defensive Interval Ratio

Latest as of June 2026: 336 days

Unicycive Therapeutics Inc defensive interval ratio. Unicycive Therapeutics Inc (UNCY) has a Defensive Interval Ratio of 336 days as of June 2026. Defensive assets of $17.24 Million (cash $-, short-term investments $17.24 Million, receivables $-) cover 336 days of daily cash needs of $51.24K/day. See working capital position of Unicycive Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.

Defensive Interval Ratio

336 days
Days of operational coverage

Defensive Assets

$17.24 Million
Cash + ST Investments + Receivables

Daily Cash Need

$51.24K
Current Liabilities ÷ 365

Current Liabilities

$18.70 Million
USD

Defensive Interval Ratio of Unicycive Therapeutics Inc (2024–2025)

Defensive interval ratio of Unicycive Therapeutics Inc from 2024 to 2025. This chart shows how Unicycive Therapeutics Inc's Defensive Interval Ratio has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the ratio stands at 336 days, meaning defensive assets of $17.24 Million can fund 336 days of operations without new revenue. Check asset resilience ratio of Unicycive Therapeutics Inc to evaluate the company's liquid asset resilience ratio.

Unicycive Therapeutics Inc Defensive Interval Ratio by Year (2024–2025)

Unicycive Therapeutics Inc defensive interval ratio by year from 2024 to 2025. The table below presents the year-by-year Defensive Interval Ratio for Unicycive Therapeutics Inc from 2024 to 2025, covering 2 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For the complete balance sheet picture, see UNCY current and non-current assets.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2025 233 days $12.07 Million $51.88K/day $- $12.07 Million ▲ +233 days
2024 0 days $0.00 $66.08K/day $- $0.00 —
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)